The BRAVO Study: A Comparative Analysis of Bupivacaine, Ropivacaine, and Levobupivacaine in Spinal Anesthesia for Lower Limb and Abdominal Surgeries

Comparison of Bupivacaine Heavy 0.5 percent Levobupivacaine Heavy 0.5 percent And Ropivacaine Heavy 0.75 percent in Subarachnoid block (SAB) in lower limb and abdominal surgeries: An Open, Comparative and Randamised Study. - BRAVO STUDY

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090268

Enrollment

Registered

2025-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K400- Bilateral inguinal hernia, with obstruction, without gangrene Health Condition 2: G20- Parkinsons disease Health Condition 3: I119- Hypertensive heart disease withoutheart failure Health Condition 4: I221- Subsequent ST elevation (STEMI) myocardial infarction of inferior wall Health Condition 5: J011- Acute frontal sinusitis Health Condition 6: J980- Diseases of bronchus, not elsewhere classified Health Condition 7: E119- Type 2 diabetes mellitus without complications H

Interventions

Intervention1: Sub Arachnoid Block with Injection Bupivacaine 0.5 Percent Heavy: Injection Bupivacaine 0.5 percent heavy will be given intrathecally and will look for the motor block sensory block and

Eligibility

Inclusion criteria

Inclusion criteria: After obtaining consent for SAB 1) American Society of Anesthesiologist grade I ,II and III well controlled Hypertension/DM and any other cardiac conditions which is not contraindicated for SAB 2) Age between 18 to 75 yrs 3) Patient of either sex 4) Undergoing lower limb and lower abdominal surgery.

Exclusion criteria

Exclusion criteria: 1)Upper abdominal surgeries (Incision extend above the umbilicus) and Lower segment cesarean section. 2)Pt on LMWH and heparin therapy. 3)Fixed cardiac output disorders like Hypertrophic cardiomyopathy,Mital stenosis and Aortic stenosis. 4)Pre-existing neurological conditions which are waxing and waning in nature like multiple sclerosis, poliomyelitis. 5)Allergic to any components of drug or its complications. 6)Any deformity of spine which can affect the natural spread of drug.

Design outcomes

Primary

Measure	Time frame
To compare the subarachnoid block (SAB) characteristics after administration of: 1)Bupivacaine Heavy 0.5% 2)Levobupivacaine Heavy 0.5% 3)Ropivacaine Heavy 0.75% Specifically, the primary objectives are: 1. Time taken to achieve sensory blockade up to T10 dermatome. 2. Time to onset of motor blockade. 3. Maximum level of block achieved. 4. Duration of sensory and motor blockade. Timepoint: Block characteristics will be assessed on 0,5,10,15,20,35,60,90 minutes	—

Measure

Time frame

To compare the subarachnoid block (SAB) characteristics after administration of: 1)Bupivacaine Heavy 0.5% 2)Levobupivacaine Heavy 0.5% 3)Ropivacaine Heavy 0.75% Specifically, the primary objectives are: 1. Time taken to achieve sensory blockade up to T10 dermatome. 2. Time to onset of motor blockade. 3. Maximum level of block achieved. 4. Duration of sensory and motor blockade. Timepoint: Block characteristics will be assessed on 0,5,10,15,20,35,60,90 minutes

—

Secondary

Measure	Time frame
Hemodynamic changeTimepoint: Monitoring of blood pressure systolic blood pressure and diastolic blood pressure at 5,10,15,30 ,60 and 90 minutes	—

Countries

India

Contacts

Public ContactDr Harshvardhan Tikle

TNMC and B.Y.L. Charitable Hospital Mumbai

tiklehrshwardhan@gmail.com9892404649

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026